NCT03246074 - Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 3, 2018

Primary Completion Date

August 9, 2022

Study Completion Date

April 3, 2023

Conditions

Ovarian Cancer

Interventions

DRUG

Fostamatinib 100 mg bid and Paclitaxel

"Drug: Fostamatinib (oral; 100 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"

DRUG

Fostamatinib 150 mg bid and Paclitaxel

"Drug: Fostamatinib (oral; 150 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"

DRUG

Fostamatinib 200 mg bid and Paclitaxel

"Drug: Fostamatinib (oral; 200 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"

Trial Locations (3)

University of Pennsylvania Health System, Philadelphia

Sibley Memorial Hospital, Washington D.C.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore